TrialInternational ophthalmology2022

TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China.

Yanling Dong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.